Castle Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Castle Biosciences generated cash of -$5,626,000, which is more than the previous year. Cash used in financing activities reached the amount of -$2,298,000 last year. Net change in cash is therefore -$24,107,000.
Cash Flow
| 2017 | -12.23M | -494.85K | 8.86M |
|---|---|---|---|
| 2018 | -12.29M | -277.03K | 15.83M |
| 2019 | 7.01M | -937K | 88.28M |
| 2020 | 9.86M | -4.74M | 305.89M |
| 2021 | -18.98M | -66.65M | 5.42M |
| 2022 | -41.65M | -166.54M | 1.51M |
| 2023 | -5.62M | -16.18M | -2.29M |
CSTL Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 122.94M | 329.63M | 409.85M | 98.84M | 4.47M | 1.21M | 5.07M |
Operating activities | |||||||
Net income | -57.46M | -67.13M | -31.29M | -10.28M | 5.27M | -6.36M | -12.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 12.33M | 10.54M | 3.40M | 472K | 358K | 323.01K | 310.82K |
Stock-based compensation expense | 51.21M | 36.32M | 21.74M | 8.30M | 1.24M | 0 | 108.69K |
| Deferred income tax benefit | 51.21M | 36.32M | 21.74M | 8.30M | 1.24M | 0 | 108.69K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -14.93M | -6.21M | -4.63M | 1.66M | -896K | -8.40M | -428.21K |
Inventories | -3.96M | -1.68M | 327K | -980K | -355K | -577.65K | -115.55K |
Accounts payable | 5.70M | 582K | -182K | 169K | 557K | 197.24K | 370.90K |
Cash generated by operating activities | -5.62M | -41.65M | -18.98M | 9.86M | 7.01M | -12.29M | -12.23M |
Investing activities | |||||||
Purchases Of Investments | -189.07M | -134.68M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -13.62M | -5.63M | -3.48M | -4.75M | -937K | -277.03K | -494.85K |
Acquisitions Net | 0 | -26.96M | -63.18M | 3K | 0 | 0 | 0 |
Cash generated by investing activities | -16.18M | -166.54M | -66.65M | -4.74M | -937K | -277.03K | -494.85K |
Financing activities | |||||||
Common Stock Issued | 269K | 833K | 3.89M | 330.04M | 65.93M | 0 | 292.71K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -5.13M | -1.68M | -781K | 0 | 0 | 0 | 0 |
Repayments of term debt | -142K | -122K | -8K | -27.35M | 20.91M | 0 | 8.57M |
Cash used in financing activities | -2.29M | 1.51M | 5.42M | 305.89M | 88.28M | 15.83M | 8.86M |
Net Change In Cash | -24.10M | -206.68M | -80.21M | 311.00M | 94.36M | 3.26M | -3.86M |
Cash at end of period | 98.84M | 122.94M | 329.63M | 409.85M | 98.84M | 4.47M | 1.21M |
| Data source | Data source | Data source | Data source | Data source |